Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?
The conventional conception of the therapy of heart failure (HF) with reduced ejection fraction has been recently modified by adding sodium-glucose co-transporter-2 (SGLT2) inhibitors to the combination consisting of beta blockers, mineralocorticoid receptor antagonists, and angiotensin receptor-ne...
Main Authors: | Alexander E. Berezin, Alexander A. Berezin |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2022-05-01
|
Series: | European Medical Journal |
Online Access: | https://www.emjreviews.com/european-medical-journal/article/sodium-glucose-co-transporter-2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-a-breakthrough-in-improvement-of-clinical-outcomes-j190221/ |
Similar Items
-
Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction
by: Bo Liang, et al.
Published: (2022-06-01) -
Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients
by: Alexander A. Berezin, et al.
Published: (2022-01-01) -
Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
by: Arjun K. Pandey, et al.
Published: (2022-04-01) -
Sodium–glucose cotransporter 2 inhibitor‐induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction
by: Luka Cavka, et al.
Published: (2021-08-01) -
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022-11-01)